{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:08:46Z","timestamp":1787497726721,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11912-023-01398-1","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:03:41Z","timestamp":1678856621000},"page":"455-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clonal Hematopoiesis and the Heart: a Toxic Relationship"],"prefix":"10.1007","volume":"25","author":[{"given":"Jeffrey L.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Easaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"1398_CR1","doi-asserted-by":"publisher","unstructured":"Meier J, Jensen JL, Dittus C, Coombs CC, Rubinstein S. Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Rev. 2022;56:100986. https:\/\/doi.org\/10.1016\/j.blre.2022.100986.","DOI":"10.1016\/j.blre.2022.100986"},{"issue":"11","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","volume":"27","author":"A Niroula","year":"2021","unstructured":"Niroula A, Sekar A, Murakami MA, Trinder M, Agrawal M, Wong WJ, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27(11):1921\u20137.","journal-title":"Nat Med"},{"issue":"14","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","volume":"35","author":"CJ Gibson","year":"2017","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598\u2013605.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41375-020-0795-z","volume":"34","author":"S Husby","year":"2020","unstructured":"Husby S, Favero F, Nielsen C, S\u00f8rensen BS, B\u00e6ch J, Grell K, et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020;34(12):3256\u201368.","journal-title":"Leukemia"},{"issue":"15","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5(15):2982\u20136.","journal-title":"Blood Adv"},{"key":"1398_CR6","doi-asserted-by":"publisher","unstructured":"Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022;3(5):385\u201393. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0177.","DOI":"10.1158\/2643-3230.BCD-21-0177"},{"key":"1398_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2021-151064","volume":"138","author":"H Bouzid","year":"2021","unstructured":"Bouzid H, Belk J, Jan M, Qi Y, Sarnowski C, Wirth S, et al. Clonal hematopoiesis is associated with reduced risk of Alzheimer\u2019s disease. Blood. 2021;138:5.","journal-title":"Blood"},{"key":"1398_CR8","doi-asserted-by":"publisher","unstructured":"Arends CM, Dimitriou S, Stahler A, Hablesreiter R, Strzelecka PM, Stein CM, Tilgner M, Saiki R, Ogawa S, Bullinger L, Modest DP, Stintzing S, Heinemann V, Damm F. Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood. 2022;139(10):1593\u201397. https:\/\/doi.org\/10.1182\/blood.2021014108.","DOI":"10.1182\/blood.2021014108"},{"issue":"2","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40(2):189\u2013201.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood.2021013531","volume":"139","author":"PG Miller","year":"2022","unstructured":"Miller PG, Qiao D, Rojas-Quintero J, Honigberg MC, Sperling AS, Gibson CJ, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022;139(3):357\u201368.","journal-title":"Blood"},{"issue":"8","key":"1398_CR11","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/bloodadvances.2020004062","volume":"5","author":"IA van Zeventer","year":"2021","unstructured":"van Zeventer IA, Salzbrunn JB, de Graaf AO, van der Reijden BA, Boezen HM, Vonk JM, et al. Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged \u226580 years. Blood Adv. 2021;5(8):2115\u201322.","journal-title":"Blood Adv"},{"key":"1398_CR12","doi-asserted-by":"publisher","unstructured":"Kim PG, Niroula A, Shkolnik V, McConkey M, Lin AE, S\u0142abicki M, Kemp JP, Bick A, Gibson CJ, Griffin G, Sekar A, Brooks DJ, Wong WJ, Cohen DN, Uddin MM, Shin WJ, Pirruccello J, Tsai JM, Agrawal M, Kiel DP, Bouxsein ML, Richards JB, Evans DM, Wein MN, Charles JF, Jaiswal S, Natarajan P, Ebert BL. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021;218(12):e20211872. https:\/\/doi.org\/10.1084\/jem.20211872.","DOI":"10.1084\/jem.20211872"},{"issue":"1","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","volume":"11","author":"TH Mouhieddine","year":"2020","unstructured":"Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11(1):2996.","journal-title":"Nat Commun"},{"issue":"1","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/s41467-021-26138-6","volume":"12","author":"KL Bolton","year":"2021","unstructured":"Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021;12(1):5975.","journal-title":"Nat Commun"},{"issue":"26","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.26465","volume":"97","author":"MK Nowakowska","year":"2022","unstructured":"Nowakowska MK, Kim T, Thompson MT, Bolton KL, Deswal A, Lin SH, et al. Association of clonal hematopoiesis mutations with clinical outcomes: a systematic review and meta-analysis. Am J Hematol. 2022;97(4):411\u201320.","journal-title":"Am J Hematol"},{"issue":"1","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","volume":"4","author":"L Dorsheimer","year":"2019","unstructured":"Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25\u201333.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","volume":"78","author":"B Yu","year":"2021","unstructured":"Yu B, Roberts MB, Raffield LM, Zekavat SM, Nguyen NQH, Biggs ML, et al. Association of clonal hematopoiesis with incident heart failure. J Am Coll Cardiol. 2021;78(1):42\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1398_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","volume":"77","author":"DA Pascual-Figal","year":"2021","unstructured":"Pascual-Figal DA, Bayes-Genis A, D\u00edez-D\u00edez M, Hern\u00e1ndez-Vicente \u00c1, V\u00e1zquez-Andr\u00e9s D, de la Barrera J, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2021;77(14):1747\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1398_CR20","first-page":"e003003","volume":"13","author":"S Cremer","year":"2020","unstructured":"Cremer S, Kirschbaum K, Berkowitsch A, John D, Kiefer K, Dorsheimer L, et al. Multiple somatic mutations for clonal hematopoiesis are associated with increased mortality in patients with chronic heart failure. Circ: Genomic Precis Med. 2020;13(4):e003003.","journal-title":"Circ: Genomic Precis Med"},{"issue":"7","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3324\/haematol.2020.264085","volume":"106","author":"T Yokokawa","year":"2021","unstructured":"Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, et al. Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms. Haematologica. 2021;106(7):1910\u201322.","journal-title":"Haematologica"},{"issue":"1","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1038\/s41467-021-26435-0","volume":"12","author":"Y Kimishima","year":"2021","unstructured":"Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K, et al. Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nat Commun. 2021;12(1):6177.","journal-title":"Nat Commun"},{"issue":"16","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jacc.2022.08.740","volume":"80","author":"M B\u00f6hme","year":"2022","unstructured":"B\u00f6hme M, Desch S, Rosolowski M, Scholz M, Krohn K, B\u00fcttner P, et al. Impact of clonal hematopoiesis in patients with cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2022;80(16):1545\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl_1","key":"1398_CR24","doi-asserted-by":"crossref","first-page":"A9334","DOI":"10.1161\/circ.144.suppl_1.9334","volume":"144","author":"MA Raddatz","year":"2021","unstructured":"Raddatz MA, Silver AJ, Farber-Eger E, Xu Y, Wells QS, Savona MR, et al. Abstract 9334: Clonal hematopoiesis is associated with incident severe aortic stenosis. Circulation. 2021;144(Suppl_1):A9334\u2013A9334.","journal-title":"Circulation"},{"issue":"8","key":"1398_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","volume":"41","author":"S Mas-Peiro","year":"2019","unstructured":"Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA, Dimmeler S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J. 2019;41(8):933\u20139.","journal-title":"Eur Heart J"},{"key":"1398_CR26","doi-asserted-by":"publisher","unstructured":"Scolari FL, Brahmbhatt DH, Abelson S, Medeiros JJF, Anker MS, Fung NL, Otsuki M, Calvillo-Arg\u00fcelles O, Lawler PR, Ross HJ, Luk AC, Anker S, Dick JE, Billia F. Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients. Am J Transplant. 2022;(12):3078\u201386. https:\/\/doi.org\/10.1111\/ajt.17172.","DOI":"10.1111\/ajt.17172"},{"issue":"13","key":"1398_CR27","doi-asserted-by":"publisher","first-page":"e146076","DOI":"10.1172\/jci.insight.146076","volume":"6","author":"S Sano","year":"2021","unstructured":"Sano S, Wang Y, Ogawa H, Horitani K, Sano M, Polizio AH, et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight. 2021;6(13):e146076.","journal-title":"JCI Insight"},{"issue":"9","key":"1398_CR28","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"P Libby","year":"2012","unstructured":"Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1160\/TH12-04-0276","volume":"108","author":"E Pardali","year":"2012","unstructured":"Pardali E, Waltenberger J. Monocyte function and trafficking in cardiovascular disease. Thromb Haemost. 2012;108(11):804\u201311.","journal-title":"Thromb Haemost"},{"issue":"9","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","volume":"16","author":"E Golia","year":"2014","unstructured":"Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16(9):435.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2018-01-829937","volume":"132","author":"M Buscarlet","year":"2018","unstructured":"Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dub\u00e9 M-P, et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018;132(3):277\u201380.","journal-title":"Blood"},{"issue":"2","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/QAD.0000000000003280","volume":"36","author":"S Wang","year":"2022","unstructured":"Wang S, Pasca S, Post WS, Langan S, Pallavajjala A, Haley L, et al. Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis. AIDS. 2022;36(11):1521\u201331.","journal-title":"AIDS"},{"issue":"2","key":"1398_CR34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.121.037388","volume":"29","author":"R Bhattacharya","year":"2022","unstructured":"Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;29(2):788\u201397.","journal-title":"Stroke"},{"issue":"09","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1055\/a-1830-2147","volume":"122","author":"AJ Murphy","year":"2022","unstructured":"Murphy AJ, Dragoljevic D, Natarajan P, Wang N. Hematopoiesis of indeterminate potential and atherothrombotic risk. Thromb Haemost. 2022;122(09):1435\u201342.","journal-title":"Thromb Haemost"},{"key":"1398_CR36","doi-asserted-by":"publisher","first-page":"103964","DOI":"10.1016\/j.ebiom.2022.103964","volume":"78","author":"S Wang","year":"2022","unstructured":"Wang S, Hu S, Luo X, Bao X, Li J, Liu M, et al. Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. eBioMed. 2022;78:103964.","journal-title":"eBioMed"},{"issue":"1","key":"1398_CR37","doi-asserted-by":"publisher","first-page":"10806","DOI":"10.1038\/ncomms10806","volume":"7","author":"AR Weber","year":"2016","unstructured":"Weber AR, Krawczyk C, Robertson AB, Ku\u015bnierczyk A, V\u00e5gb\u00f8 CB, Schuermann D, et al. Biochemical reconstitution of TET1\u2013TDG\u2013BER-dependent active DNA demethylation reveals a highly coordinated mechanism. Nat Commun. 2016;7(1):10806.","journal-title":"Nat Commun"},{"issue":"6047","key":"1398_CR38","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.1210597","volume":"333","author":"S Ito","year":"2011","unstructured":"Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300\u20133.","journal-title":"Science"},{"issue":"9","key":"1398_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/cas.12484","volume":"105","author":"H Nakajima","year":"2014","unstructured":"Nakajima H, Kunimoto H. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci. 2014;105(9):1093\u20139.","journal-title":"Cancer Sci"},{"issue":"1","key":"1398_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronn\u00e9 L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25\u201338.","journal-title":"Cancer Cell"},{"issue":"1","key":"1398_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11\u201324.","journal-title":"Cancer Cell"},{"issue":"35","key":"1398_CR42","doi-asserted-by":"publisher","first-page":"14566","DOI":"10.1073\/pnas.1112317108","volume":"108","author":"M Ko","year":"2011","unstructured":"Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A. 2011;108(35):14566\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1398_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/srep00273","volume":"2","author":"H Kunimoto","year":"2012","unstructured":"Kunimoto H, Fukuchi Y, Sakurai M, Sadahira K, Ikeda Y, Okamoto S, et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep. 2012;2:273.","journal-title":"Sci Rep"},{"issue":"10","key":"1398_CR44","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/leu.2012.94","volume":"26","author":"K Shide","year":"2012","unstructured":"Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia. 2012;26(10):2216\u201323.","journal-title":"Leukemia"},{"key":"1398_CR45","doi-asserted-by":"publisher","unstructured":"Cheng S, Zhang W, Inghirami G, Tam W. Mutation analysis links angioimmunoblastic T cell lymphoma to clonal hematopoiesis and smoking. Elife. 2021;10:e66395. https:\/\/doi.org\/10.7554\/eLife.66395.","DOI":"10.7554\/eLife.66395"},{"issue":"10","key":"1398_CR46","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","volume":"4","author":"NE Lewis","year":"2020","unstructured":"Lewis NE, Petrova-Drus K, Huet S, Epstein-Peterson ZD, Gao Q, Sigler AE, et al. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Adv. 2020;4(10):2261\u201371.","journal-title":"Blood Adv"},{"issue":"9","key":"1398_CR47","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"5","key":"1398_CR48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2011.326","volume":"26","author":"S Weissmann","year":"2012","unstructured":"Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26(5):934\u201342.","journal-title":"Leukemia"},{"issue":"6327","key":"1398_CR49","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842\u20137.","journal-title":"Science"},{"issue":"23","key":"1398_CR50","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.121.057599","volume":"145","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R, Ostriker AC, Xie Y, Dave JM, Gamez-Mendez A, Chatterjee P, et al. Histone acetyltransferases p300 and CBP coordinate distinct chromatin remodeling programs in vascular smooth muscle plasticity. Circulation. 2022;145(23):1720\u201337.","journal-title":"Circulation"},{"issue":"6","key":"1398_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.120.050553","volume":"144","author":"AC Ostriker","year":"2021","unstructured":"Ostriker AC, Xie Y, Chakraborty R, Sizer AJ, Bai Y, Ding M, et al. TET2 protects against vascular smooth muscle cell apoptosis and intimal thickening in transplant vasculopathy. Circulation. 2021;144(6):455\u201370.","journal-title":"Circulation"},{"issue":"4","key":"1398_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.120.049715","volume":"143","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Xia L, Fan S, Zheng J, Qin J, Fan X, et al. Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation. Circulation. 2021;143(4):354\u201371.","journal-title":"Circulation"},{"issue":"18","key":"1398_CR53","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.113.002887","volume":"128","author":"R Liu","year":"2013","unstructured":"Liu R, Jin Y, Tang WH, Qin L, Zhang X, Tellides G, et al. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation. 2013;128(18):2047\u201357.","journal-title":"Circulation"},{"issue":"18","key":"1398_CR54","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1161\/CIRCULATIONAHA.113.006092","volume":"128","author":"DA Prosdocimo","year":"2013","unstructured":"Prosdocimo DA, Jain R, Jain MK. UnTEThering (smooth muscle) cell plasticity. Circulation. 2013;128(18):2002\u20134.","journal-title":"Circulation"},{"issue":"8","key":"1398_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","volume":"71","author":"S Sano","year":"2018","unstructured":"Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1B\/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71(8):875\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"1398_CR56","doi-asserted-by":"publisher","unstructured":"Wang Y, Sano S, Yura Y, Ke Z, Sano M, Oshima K, Ogawa H, Horitani K, Min KD, Miura-Yura E, Kour A, Evans MA, Zuriaga MA, Hirschi KK, Fuster JJ, Pietras EM, Walsh K. Tet2 mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight. 2020;5(6):e135204. https:\/\/doi.org\/10.1172\/jci.insight.135204.","DOI":"10.1172\/jci.insight.135204"},{"issue":"3","key":"1398_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","volume":"123","author":"S Sano","year":"2018","unstructured":"Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123(3):335\u201341.","journal-title":"Circ Res"},{"issue":"10","key":"1398_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/hmg\/ddab046","volume":"30","author":"H Tao","year":"2021","unstructured":"Tao H, Xu W, Qu W, Gao H, Zhang J, Cheng X, et al. Loss of ten-eleven translocation 2 induces cardiac hypertrophy and fibrosis through modulating ERK signaling pathway. Hum Mol Genet. 2021;30(10):865\u201379.","journal-title":"Hum Mol Genet"},{"issue":"19","key":"1398_CR59","doi-asserted-by":"publisher","first-page":"e026154","DOI":"10.1161\/JAHA.122.026154","volume":"11","author":"KD Min","year":"2022","unstructured":"Min KD, Polizio AH, Kour A, Thel MC, Walsh K. Experimental ASXL1-mediated clonal hematopoiesis promotes inflammation and accelerates heart failure. J Am Heart Assoc. 2022;11(19):e026154.","journal-title":"J Am Heart Assoc"},{"key":"1398_CR60","doi-asserted-by":"crossref","unstructured":"\u2022 Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 2022;7(5):521\u20138. \u201cTET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial\u201d: TET2 mutations are associated with improved responses to the IL-1\u03b2 neutralizing antibody, canakinumab. Studies like this may develop a clinical role for assessing CH in patients with cardiovascular disease in guiding therapy choices.","DOI":"10.1001\/jamacardio.2022.0386"},{"key":"1398_CR61","doi-asserted-by":"publisher","unstructured":"Uddin MDM, Nguyen NQH, Yu B, Brody JA, Pampana A, Nakao T, Fornage M, Bressler J, Sotoodehnia N, Weinstock JS, Honigberg MC, Nachun D, Bhattacharya R, Griffin GK, Chander V, Gibbs RA, Rotter JI, Liu C, Baccarelli AA, Chasman DI, Whitsel EA, Kiel DP, Murabito JM, Boerwinkle E, Ebert BL, Jaiswal S, Floyd JS, Bick AG, Ballantyne CM, Psaty BM, Natarajan P, Conneely KN. Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. Nat Commun. 2022;13(1):5350. https:\/\/doi.org\/10.1038\/s41467-022-33093-3.\u00a0","DOI":"10.1038\/s41467-022-33093-3"},{"issue":"11","key":"1398_CR62","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728\u201346.","journal-title":"Circ Res"},{"issue":"10289","key":"1398_CR63","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1398_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","volume":"141","author":"AG Bick","year":"2020","unstructured":"Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141(2):124\u201331.","journal-title":"Circulation"},{"key":"1398_CR65","unstructured":"\u2022 Shin TH, Zhou Y, Chen S, Cordes S, Grice MZ, Fan X, et al. A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for\u00a0testing interventions. Blood. 2022;140(16):1774\u201389. \u201cA macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for\u00a0testing interventions\u201d: In this primate study, blocking IL-6 with tocilizumab prevented the expansion of TET2-disrupted clones, showing that clonal expansion can be prevented."},{"issue":"10","key":"1398_CR66","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1172\/JCI90312","volume":"128","author":"B Edelmann","year":"2018","unstructured":"Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, et al. JAK2-V617F promotes venous thrombosis through \u03b2 1\/\u03b2 2 integrin activation. J Clin Investig. 2018;128(10):4359\u201371.","journal-title":"J Clin Investig"},{"issue":"Suppl_1","key":"1398_CR67","doi-asserted-by":"publisher","first-page":"A12959","DOI":"10.1161\/circ.144.suppl_1.12959","volume":"144","author":"O Dikilitas","year":"2021","unstructured":"Dikilitas O, Saadatagah S, Satterfield B, Kullo IJ. Abstract 12959: clonal hematopoiesis of indeterminate potential predicts incident venous thromboembolism in the UK biobank cohort. Circulation. 2021;144(Suppl_1):A12959\u2013A12959.","journal-title":"Circulation"},{"issue":"03","key":"1398_CR68","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1055\/s-0041-1733856","volume":"05","author":"S Soudet","year":"2021","unstructured":"Soudet S, Jedraszak G, Evrard O, Marolleau JP, Garcon L, Pietri MAS. Is hematopoietic clonality of indetermined potential a risk factor for pulmonary embolism? TH Open. 2021;05(03):e338\u201342.","journal-title":"TH Open"},{"issue":"436","key":"1398_CR69","doi-asserted-by":"publisher","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","volume":"10","author":"O Wolach","year":"2018","unstructured":"Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1398_CR70","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"1398_CR71","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.119.044320","volume":"141","author":"F Potus","year":"2020","unstructured":"Potus F, Pauciulo MW, Cook EK, Zhu N, Hsieh A, Welch CL, et al. Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension. Circulation. 2020;141(24):1986\u20132000.","journal-title":"Circulation"},{"key":"1398_CR72","doi-asserted-by":"crossref","unstructured":"\u2022 Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592(7853):296\u2013301. \u201cThe AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis\u201d: In this Jak2VF model of CH, CH was associated with increased proliferation and glycolytic metabolism in macrophages leading to DNA stress and subsequent activation of the AIM2 inflammasome and exacerbation of atherosclerosis. Aberrant cytokine secretion is not the only mechanism through which clonal myeloid cells worsen cardiovascular health outcomes.","DOI":"10.1038\/s41586-021-03341-5"},{"issue":"11","key":"1398_CR73","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","volume":"123","author":"W Wang","year":"2018","unstructured":"Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in <i>Jak2<\/i><sup><i>V617F<\/i><\/sup> mice. Circ Res. 2018;123(11):e35\u201347.","journal-title":"Circ Res"},{"issue":"4","key":"1398_CR74","doi-asserted-by":"publisher","first-page":"108326","DOI":"10.1016\/j.celrep.2020.108326","volume":"33","author":"JJ Fuster","year":"2020","unstructured":"Fuster JJ, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, et al. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep. 2020;33(4):108326.","journal-title":"Cell Rep"},{"issue":"4","key":"1398_CR75","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ekir.2022.01.1064","volume":"7","author":"S Denicol\u00f2","year":"2022","unstructured":"Denicol\u00f2 S, Vogi V, Keller F, Th\u00f6ni S, Eder S, Heerspink HJL, et al. Clonal hematopoiesis of indeterminate potential and diabetic kidney disease: a nested case-control study. Kidney Int Reports. 2022;7(4):876\u201388.","journal-title":"Kidney Int Reports"},{"issue":"2","key":"1398_CR76","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41375-021-01382-3","volume":"36","author":"AAZ Dawoud","year":"2022","unstructured":"Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia. 2022;36(2):507\u201315.","journal-title":"Leukemia"},{"issue":"1","key":"1398_CR77","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1038\/s41598-022-09604-z","volume":"12","author":"MG Levin","year":"2022","unstructured":"Levin MG, Nakao T, Zekavat SM, Koyama S, Bick AG, Niroula A, et al. Genetics of smoking and risk of clonal hematopoiesis. Sci Rep. 2022;12(1):7248.","journal-title":"Sci Rep"},{"issue":"10","key":"1398_CR78","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","volume":"34","author":"AA Dawoud","year":"2020","unstructured":"Dawoud AA, Tapper WJ, Cross NC. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34(10):2660\u201372.","journal-title":"Leukemia"},{"issue":"9","key":"1398_CR79","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2021.1678","volume":"6","author":"R Bhattacharya","year":"2021","unstructured":"Bhattacharya R, Zekavat SM, Uddin MM, Pirruccello J, Niroula A, Gibson C, et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 2021;6(9):1069\u201377.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"1398_CR80","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219\u201326.","journal-title":"Nat Genet"},{"issue":"12","key":"1398_CR81","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971\u20137.","journal-title":"Heart"},{"issue":"6","key":"1398_CR82","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/CIRCRESAHA.121.319314","volume":"129","author":"Y Yura","year":"2021","unstructured":"Yura Y, Miura-Yura E, Katanasaka Y, Min K-D, Chavkin N, Polizio AH, et al. The cancer therapy-related clonal hematopoiesis driver gene Ppm1d promotes inflammation and non-ischemic heart failure in mice. Circ Res. 2021;129(6):684\u201398.","journal-title":"Circ Res"},{"issue":"3","key":"1398_CR83","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-82.e4.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"1398_CR84","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23(5):700-13.e6.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1398_CR85","first-page":"141","volume":"4","author":"K Hatakeyama","year":"2022","unstructured":"Hatakeyama K, Hieda M, Semba Y, Moriyama S, Wang Y, Maeda T, et al. TET2 clonal hematopoiesis is associated with anthracycline-induced cardiotoxicity in patients with lymphoma. JACC: CardioOncol. 2022;4(1):141\u20133.","journal-title":"JACC: CardioOncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01398-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:43:00Z","timestamp":1744195380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01398-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01398-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"31 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffrey L. Jensen is an AbbVie and Pfizer shareholder. Saumya Easaw declares no conflicts of interest. Travis Anderson declares no conflicts of interest. Yash Varma declares no conflicts of interest. Jiandong Zhang declares no conflicts of interest. Brian C Jensen has served as a consultant for AstraZeneca. Catherine C. Coombs has served as a consultant for AbbVie, has served on steering committees for AbbVie and Loxo Oncology, has served on independent review committees for AbbVie and Octapharma, has served on Speaker\u2019s Bureau for AbbVie, has received honoraria from AbbVie, AstraZeneca, Beigene, Genentech, Loxo Oncology, MEI Pharma, Novartis, TG Therapeutics, is a CTI Biopharma and Bluebird bio shareholder, and has received research funding (paid to the institution) from AbbVie and Loxo Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}